Cancer News and Research

Latest Cancer News and Research

New CLF survey on the unawareness of Canadians in contracting food-related illnesses

A new survey from the Canadian Liver Foundation (CLF) reveals more than half of Canadians over the age of 25 (57 per cent) are concerned about contracting food-related illnesses like hepatitis A, but many are unaware that their everyday food preparation and consumption habits may put them at risk for this liver disease

17 Sep 2009

Cancer patients struggles with huge drug costs

Canada's patchwork system of drug coverage is leading to financial hardship for many cancer patients, says a Canadian Cancer Society report released today.

17 Sep 2009

Deterioration in brain function following breast cancer therapy affects quality of life: Study

One of the most problematic side effects of cancer treatment, chemobrain - a range of symptoms including memory loss, inability to concentrate, difficulty thinking and other subtle cognitive changes following chemotherapy - seriously diminishes women's quality of life and daily functioning.

17 Sep 2009

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.

17 Sep 2009

GENova Biotherapeutics signs collaboration deal with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed a collaboration deal with Beckpharma Ltd.

17 Sep 2009

Discovery of key molecule may yield new therapies for AIDS and cancer

Discovery by Hebrew University of Jerusalem researchers of an additional role for a key molecule in our bodies provides a further step in world-wide efforts to develop genetic regulation aimed at controlling many diseases, including AIDS and various types of cancers.

17 Sep 2009

NIH to fund grants for epigenetic research

The National Institutes of Health announced today that it will fund 22 grants on genome-wide studies of how epigenetic changes -- chemical modifications to genes that result from diet, aging, stress, or environmental exposures -- define and contribute to specific human diseases and biological processes.

17 Sep 2009

CHUM installs CyberKnife system for effective cancer treatment in Canada

Accuray Incorporated, a global leader in the field of radiosurgery today announced that Centre Hospitalier de l'Universite de Montreal (CHUM) has installed a CyberKnife(R) Robotic Radiosurgery System at Hopital Notre-Dame du CHUM, in Montreal, Canada.

17 Sep 2009

Advanced radiosurgery technology utilized by Cyberknife for effective cancer treatment

Cyberknife of Long Island has become the first cancer center in New York to treat tumors with the most advanced radiosurgery technology available to date.

17 Sep 2009

NASDAQ Stock Market issues notification letter to GenVec

On September 15, 2009, GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5450(a)(5).

17 Sep 2009

BioMedReports.Com's news report on CEL-SCI's key developments

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation.

17 Sep 2009

Mayo Clinic Health Letter discusses kidney stone treatment options

Ordinary, loud snoring doesn't seem to be harmful, according to the September issue of Mayo Clinic Health Letter. But snorers still may want to seek treatment to stop snoring, reduce embarrassment and improve sleep for themselves and their bed partner.

17 Sep 2009

Pharmabcine raises funds to develop therapeutic antibodies in the area of cancer and inflammation

PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009

Underlying malignancies can cause rebleeding after negative angiography

Acute non-variceal gastrointestinal bleeding accounts for approximately 20% of emergency room visits and 5% of admissions. Although endoscopy has been used as a first-line treatment option in patients with gastrointestinal bleeding, angiographic intervention can be used as a safe diagnostic and treatment method in patients with gastrointestinal bleeding that is refractory to endoscopic treatment.

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

17 Sep 2009

Liver transplantation performed in a six-month old infant

Ila and her worried parents were referred to Lucile Packard Children's Hospital at Stanford, home of the busiest pediatric liver transplant team in the nation. The hospital's team performed more liver transplants in 2008 – the most recent reporting period – than any other U.S. children's hospital, according to the United Network for Organ Sharing. They also did the largest number of surgeries in infants like Ila, who were younger than one year when they received a transplant.

17 Sep 2009

Seegene awarded patent in the U.S. and Europe for Annealing Control Primer

Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.

17 Sep 2009